Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCR300 for Preventing AML Recurrence Post-Transplant
NCT06441084Phase 1Not yet recruiting
- Sponsor
- Nuwacell Biotechnologies
- Start
- Jun 2024
- Primary completion
- Dec 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of NCR-300 in acute myeloid leukemia (AML), sponsored by Nuwacell Biotechnologies. Primary endpoints: Dose-Limiting Toxicity at 4 weeks and Adverse Events / Serious Adverse Events at 1 year. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
NCR-300
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06441084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441084.